Long-Term Follow-Up of Lentigo Maligna Patients Treated with Imiquimod 5% Cream
Background: The study investigated the long-term efficacy of imiquimod 5% cream for LM, with a focus on disease recurrence and the possible prognostic factors of disease-free survival (DFS) in a cohort, with long-term follow-up. Methods: Consecutive patients with histologically confirmed LM were inc...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/5/1546 |
| _version_ | 1797615636275265536 |
|---|---|
| author | S. Morteza Seyed Jafari Flavia Folini-Huesser Simone Cazzaniga Robert E. Hunger |
| author_facet | S. Morteza Seyed Jafari Flavia Folini-Huesser Simone Cazzaniga Robert E. Hunger |
| author_sort | S. Morteza Seyed Jafari |
| collection | DOAJ |
| description | Background: The study investigated the long-term efficacy of imiquimod 5% cream for LM, with a focus on disease recurrence and the possible prognostic factors of disease-free survival (DFS) in a cohort, with long-term follow-up. Methods: Consecutive patients with histologically confirmed LM were included. Imiquimod 5% cream was applied until weeping erosion appeared on the LM-affected skin. The evaluation was performed through clinical examination and dermoscopy. Results: We analyzed 111 patients with LM (median age: 72 years, 61.3% women) with tumor clearance after imiquimod therapy, with a median follow-up of 8 years. The overall patient survival rates were 85.5% (95% confidence interval (CI): 78.5–92.6) and 70.4% (95% CI: 60.3–80.5) at 5 and 10 years, respectively. Among the 23 patients (20.1%) with relapse at follow-up, 17 (73.9%) were treated with surgery, five (21.7%) continued imiquimod therapy, and one (4.3%) underwent both surgery and radiotherapy. After adjustment for age and LM area in multivariable models, localization of LM in the nasal region was identified as a prognostic factor for DFS (HR = 2.66; 95% CI: 1.06–6.64). Conclusion: If surgical excision is not possible due to the patients’ age/comorbidities or critical cosmetic localization, imiquimod could provide optimal outcomes with an optimal risk of relapse for the management of LM. |
| first_indexed | 2024-03-11T07:28:24Z |
| format | Article |
| id | doaj.art-24fceccce6a14be1bc25800804847a9e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T07:28:24Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-24fceccce6a14be1bc25800804847a9e2023-11-17T07:25:32ZengMDPI AGCancers2072-66942023-02-01155154610.3390/cancers15051546Long-Term Follow-Up of Lentigo Maligna Patients Treated with Imiquimod 5% CreamS. Morteza Seyed Jafari0Flavia Folini-Huesser1Simone Cazzaniga2Robert E. Hunger3Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, SwitzerlandDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, SwitzerlandDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, SwitzerlandDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, 3012 Bern, SwitzerlandBackground: The study investigated the long-term efficacy of imiquimod 5% cream for LM, with a focus on disease recurrence and the possible prognostic factors of disease-free survival (DFS) in a cohort, with long-term follow-up. Methods: Consecutive patients with histologically confirmed LM were included. Imiquimod 5% cream was applied until weeping erosion appeared on the LM-affected skin. The evaluation was performed through clinical examination and dermoscopy. Results: We analyzed 111 patients with LM (median age: 72 years, 61.3% women) with tumor clearance after imiquimod therapy, with a median follow-up of 8 years. The overall patient survival rates were 85.5% (95% confidence interval (CI): 78.5–92.6) and 70.4% (95% CI: 60.3–80.5) at 5 and 10 years, respectively. Among the 23 patients (20.1%) with relapse at follow-up, 17 (73.9%) were treated with surgery, five (21.7%) continued imiquimod therapy, and one (4.3%) underwent both surgery and radiotherapy. After adjustment for age and LM area in multivariable models, localization of LM in the nasal region was identified as a prognostic factor for DFS (HR = 2.66; 95% CI: 1.06–6.64). Conclusion: If surgical excision is not possible due to the patients’ age/comorbidities or critical cosmetic localization, imiquimod could provide optimal outcomes with an optimal risk of relapse for the management of LM.https://www.mdpi.com/2072-6694/15/5/1546imiquimod therapylentigo malignanon-invasive therapy |
| spellingShingle | S. Morteza Seyed Jafari Flavia Folini-Huesser Simone Cazzaniga Robert E. Hunger Long-Term Follow-Up of Lentigo Maligna Patients Treated with Imiquimod 5% Cream Cancers imiquimod therapy lentigo maligna non-invasive therapy |
| title | Long-Term Follow-Up of Lentigo Maligna Patients Treated with Imiquimod 5% Cream |
| title_full | Long-Term Follow-Up of Lentigo Maligna Patients Treated with Imiquimod 5% Cream |
| title_fullStr | Long-Term Follow-Up of Lentigo Maligna Patients Treated with Imiquimod 5% Cream |
| title_full_unstemmed | Long-Term Follow-Up of Lentigo Maligna Patients Treated with Imiquimod 5% Cream |
| title_short | Long-Term Follow-Up of Lentigo Maligna Patients Treated with Imiquimod 5% Cream |
| title_sort | long term follow up of lentigo maligna patients treated with imiquimod 5 cream |
| topic | imiquimod therapy lentigo maligna non-invasive therapy |
| url | https://www.mdpi.com/2072-6694/15/5/1546 |
| work_keys_str_mv | AT smortezaseyedjafari longtermfollowupoflentigomalignapatientstreatedwithimiquimod5cream AT flaviafolinihuesser longtermfollowupoflentigomalignapatientstreatedwithimiquimod5cream AT simonecazzaniga longtermfollowupoflentigomalignapatientstreatedwithimiquimod5cream AT robertehunger longtermfollowupoflentigomalignapatientstreatedwithimiquimod5cream |